| Literature DB >> 16864979 |
R J J van Neerven1, E F Knol, A Ejrnaes, P A Würtzen.
Abstract
It is well established that both the production of IgE by B lymphocytes and the maturation and recruitment of eosinophils in late-phase reactions are dependent on the activation of allergen-specific type-2 T-helper cells. What is less well known is the fact that efficient activation of allergen-specific T cells upon low-dose exposure to allergens is critically dependent on IgE-mediated or -facilitated allergen presentation. In fact, changes in the level of IgE-mediated allergen presentation may account for many of the immunological effects described for specific immunotherapy or anti-IgE treatment. This review aims to summarize the current knowledge, and will discuss the clinical relevance of blocking IgG antibodies induced by specific immunotherapy and anti-IgE monoclonal antibodies that both interfere with IgE-mediated allergen presentation. Copyright (c) 2006 S. Karger AG, Basel.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16864979 DOI: 10.1159/000094714
Source DB: PubMed Journal: Int Arch Allergy Immunol ISSN: 1018-2438 Impact factor: 2.749